BridgeBio reports $353M Q3 revenue, advances key drug approvals, and prepares launches for genetic condition treatments.

BridgeBio Pharma announced $353.2 million in total revenues for Q3 2026, driven mainly by $253.2 million from U.S. sales of Attruby, a treatment for transthyretin amyloid cardiomyopathy. The company highlighted positive real-world data showing Attruby's clinical benefits over competitors and progress in its pipeline, including upcoming FDA review dates for BBP-418 (LGMD2I/R9), oral infigratinib (achondroplasia), and encaleret (ADH1). With $1.5 billion in cash and securities, BridgeBio is well-funded to support multiple product launches and ongoing development. Investors should watch for regulatory decisions and new clinical data expected through early 2028.

BridgeBio Pharma's stock is trading at USD 70.30 on Pluang, down 0.73% for the day as of Oct 30, 2026 03:11 WIB. The stock's market cap stands at $13.84 billion, with a 52-week range between $61.37 and $90.17, reflecting active investor interest despite recent declines.